Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference, on Thursday, Jan. 14.
Mr. Luther will discuss the status of the Company and milestones it met throughout the year, including receiving two FDA-granted Fast Track designations for its lead compound CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer and the treatment of acute myeloid leukemia (AML). He will also highlight the most recent trial launches, including a Phase 2 clinical trial for patients with clear cell sarcoma of soft tissue.
“Rafael has achieved significant milestones in 2020, despite the unique challenges presented amid the COVID-19 pandemic,” said Sanjeev Luther, President and CEO of Rafael. “We are eager to highlight the successes over the past year during the presentation, as well as discuss the key learnings that we believe will propel us forward in 2021. It is truly humbling to see how we continue to come closer to our ultimate goal of treating hard-to-treat cancers with a novel approach to therapy, cancer metabolism.”
The presentation will be webcast and accessible for companies presenting and attending the J.P. Morgan Health Conference. An archived replay of the presentation will be available on theCompany's website, rafaelpharma.com.
About CPI-613® (devimistat)
About Rafael Pharmaceuticals, Inc.
Safe Harbor Statement
In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Rafael Media Contact:
On Premise Strategies: CBRS and Private LTE
ROI Use Case
How to Strategically Leverage New Connectivity Options